Atossa Therapeutics, INC Form 4 insider transactions

Atossa Therapeutics director Richard I. Steinhart was granted 10,000 restricted stock units as part of his compensation.

Atossa Therapeutics, Inc. reports a grant of 10,000 restricted stock units to Director Shu-Chih Chen, with vesting scheduled for May 12, 2027.

H. Lawrence Remmel, a Director at Atossa Therapeutics, Inc., was granted 10,000 Restricted Stock Units (RSUs) on May 12, 2026, which will vest one year later.

Jonathan Finn, a Director at Atossa Therapeutics, Inc., acquired 10,000 restricted stock units (RSUs) on May 12, 2026, with vesting scheduled for May 12, 2027.

Stephen J. Galli, a Director at Atossa Therapeutics, Inc., was granted 10,000 restricted stock units on May 12, 2026.

Tessa Cigler, a Director at Atossa Therapeutics, Inc., was granted 10,000 Restricted Stock Units (RSUs) on May 12, 2026, which are set to vest one year later.

Atossa Therapeutics' President & CEO, Steven C. Quay, was granted 65,000 restricted stock units, vesting over three years.

ATOSSA THERAPEUTICS' Chief Financial Officer, Daniel Mark James, was granted 63,000 restricted stock units vesting over three years.

ATOSSA THERAPEUTICS CEO Steven C. Quay amended a Form 4 filing to correct the number of restricted stock units acquired, alongside new stock option grants.

Atossa Therapeutics' President and CEO, Steven C. Quay, acquired 325,203 restricted stock units and 950,000 stock options on January 20, 2026, signaling increased insider ownership.

ATOSSA THERAPEUTICS' Chief Financial Officer, Mark James Daniel, was granted 578,000 stock options with an exercise price of $1.03, vesting over four years.

Atossa Therapeutics' CEO, Steven Quay, recently purchased 11,239 shares of common stock at an average price of $0.8797 per share.

Director Jonathan Finn acquired stock options in Atossa Therapeutics, vesting quarterly over 12 months, exercisable at $0.99.

Director Chen Shu-Chih of Atossa Therapeutics acquired stock options for 125,000 shares on May 15, 2025.

Atossa Therapeutics' CEO, Steven Quay, was granted stock options to purchase 1,366,062 shares of common stock.

Heather Rees, CFO of Atossa Therapeutics, was granted stock options to purchase 543,785 shares of common stock at an exercise price of $0.99 on May 15, 2025.

Stephen J. Galli, a director of Atossa Therapeutics, acquired stock options exercisable for 125,000 shares of common stock.

Director H. Lawrence Remmel acquired stock options in Atossa Therapeutics, signaling potential confidence in the company's future.

Director Richard I. Steinhart reports acquisition of Atossa Therapeutics stock options.

Director Tessa Cigler acquired stock options in Atossa Therapeutics, according to a recent SEC filing.

Director Remmel H. Lawrence of Atossa Therapeutics, Inc. purchased 10,000 shares of common stock at $0.7 per share on March 26, 2025.

Director Jonathan Finn of Atossa Therapeutics acquired 125,000 stock options on June 27, 2024, according to a Form 4 filing with the SEC.

Director H. Lawrence Remmel acquired stock options in Atossa Therapeutics, Inc. on June 27, 2024.

Richard I. Steinhart, a director of Atossa Therapeutics, acquired stock options for 125,000 shares on June 27, 2024.

Director Chen Shu-Chih of Atossa Therapeutics acquires stock options exercisable for 125,000 shares of common stock.

Heather Rees, SVP, Finance and Accounting at Atossa Therapeutics, reports the acquisition of stock options.

Atossa Therapeutics' CEO, Steven Quay, was granted 1,795,100 stock options on June 27, 2024, exercisable at $1.05 per share.

Director Stephen J. Galli acquired stock options in Atossa Therapeutics, Inc. on June 27, 2024.

Director Tessa Cigler acquired 125,000 stock options in Atossa Therapeutics on June 27, 2024, at an exercise price of $1.05.

Director Jonathan Finn purchased 25,000 shares of Atossa Therapeutics at an average price of $1.77 on April 10, 2024.